Anticoagulant Choice for Nonvalvular Atrial Fibrillation and Venous Thromboembolism

Primary Recommendation Hierarchy

The American College of Cardiology recommends DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) as the first-line treatment for nonvalvular atrial fibrillation and venous thromboembolism due to their superior efficacy and safety compared to warfarin 1, 2
Warfarin is reserved for specific contraindications to DOACs, such as mechanical prosthetic heart valves or moderate-to-severe mitral stenosis 1, 4, 5
Low-Molecular-Weight Heparin (LMWH) is recommended for short-term bridging or when oral agents are contraindicated 1, 4
Unfractionated Heparin is reserved for acute settings requiring rapid reversal capability 6

In cancer patients with atrial fibrillation, DOACs show significant reductions in both thromboembolic events and major bleeding complications compared to warfarin 1, 4

DOACs are contraindicated in patients with mechanical prosthetic heart valves, and warfarin must be used instead 1, 4, 3
DOACs are also contraindicated in patients with moderate-to-severe mitral stenosis, and warfarin must be used instead 1, 4, 3

Warfarin is preferred over DOACs in patients with severe renal dysfunction (CrCl <15 mL/min) 1, 4
Warfarin is also preferred in patients with left ventricular thrombus, with a target INR of 2.0-3.0 5
Significant drug-drug interactions with CYP3A4/P-gp inhibitors/inducers that preclude DOAC use also favor warfarin 1, 4

LMWH is appropriate for short-term anticoagulation in cancer patients unsuitable for DOACs, and for bridging therapy when transitioning from warfarin to procedures 1, 4, 7
Unfractionated heparin is reserved for acute settings requiring immediate anticoagulation with potential need for rapid reversal, and for patients with severe renal impairment where LMWH clearance is problematic 6

When DOACs are appropriate, the choice of specific agent should be based on renal function, bleeding risk, drug interactions, and patient factors 1, 4, 7
For hemophilia patients requiring anticoagulation, DOACs are preferred over warfarin when baseline factor VIII or IX levels are maintained >20 IU/dL 2

For low-risk procedures, DOACs should be omitted on the morning of the procedure, while warfarin can be continued if INR is therapeutic 7
For high-risk procedures, DOACs should be stopped 3 days before (5 days for dabigatran if CrCl 30-50 mL/min), with no bridging needed 7

DOACs do not require routine laboratory monitoring 2
Warfarin requires INR monitoring weekly during initiation, monthly when stable, and within one week before high-risk procedures, with a target time in therapeutic range exceeding 70% 5, 7